Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 29, 2016

View Archived Issues

DKN-01 plus paclitaxel well tolerated in patients with EC or GEJ

The Hereditary Neuropathy Foundation announces partnership with Acetylon Pharmaceuticals

Chugai reviews key regulatory and pipeline events of fourth quarter 2015

Avax Technologies announces results of its OVAX phase I/II clinical trial

Akashi Therapeutics suspends dosing and enrollment in HT-100 trial

Synthetic lethality approach used to identify antibacterial compounds

FDA grants breakthrough therapy designation for Lynparza as treatment of prostate cancer

Genticel reports phase II trial results for ProCervix

Sophiris reports initial data from phase IIa trial of topsalysin in prostate cancer

Gruenenthal discloses phosphodiesterase 4B inhibitors

Novogen patent reports tropomyosin alpha-3 chain inhibitors

HEC Pharm presents FLT3 inhibitors

Biogen divulges IRAK-4 inhibitors

Cancer Research Technology and MSD form PRMT5 inhibitor collaboration

Phase I study of MERS vaccine begins

Radius Health announces clinical collaboration to evaluate RAD-1901 combination regimens

Giant multivalent glycofullerenes inhibit cell infection by Ebola virus

FDA grants fast track designation to IMC-1 combination for fibromyalgia

FDA approves Merck & Co.'s Zepatier for HCV infection

FDA approves Onzetra Xsail for acute treatment of migraine

Phase III Opdivo trial meets endpoint, stopped early

Cerenis starts phase III trial of CER-001 in familial primary hypoalphalipoproteinemia

ENB Therapeutics' ENB-001 granted FDA orphan designation for melanoma

Agilis and NTU enter collaboration for AADC deficiency gene therapy

FDA approves Halaven in new indication

Biofrontera reports promising phase III results for Ameluz in basal cell carcinoma

FDA says Exelixis's NDA for cabozantinib now complete

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...
Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC
BioWorld Science
At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, researchers from Actinium Pharmaceuticals Inc. presented preclinical efficacy data...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
SKL-35501 shows broad antitumor activity in solid tumors
BioWorld Science
Neurotensin receptor 1 (NTSR1) is overexpressed in several aggressive solid tumors, including colorectal and pancreatic cancer, making it a promising therapeutic...